Cristina Cruz

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

Thomas Powles, Joseph P. Eder, Gregg Fine et al. · Nature · 2014 · 2.4K citations

Urology, Oncology, Genitourinary Cancer +5

Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer

Leisha A. Emens, Cristina Cruz, Joseph P. Eder et al. · JAMA Oncology · 2018 · 774 citations · Full text

RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer

Cristina Cruz, Marta Castroviejo‐Bermejo, Sara Gutiérrez‐Enríquez et al. · Annals of Oncology · 2018 · 410 citations · Full text

CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer

Shawn F. Johnson, Cristina Cruz, Ann Katrin Greifenberg et al. · Cell Reports · 2016 · 279 citations · Full text

The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin

Yifan Wang, Andrea J. Bernhardy, Cristina Cruz et al. · Cancer Research · 2016 · 267 citations · Full text